Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Annual General Meeting

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

44.7 USD

Average target price

54.24 USD

Spread / Average Target

+21.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-12.88%	90.6B
NOVO NORDISK A/S	+25.56%	556B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+7.95%	296B
ASTRAZENECA PLC	+13.02%	233B
NOVARTIS AG	+5.31%	201B
ROCHE HOLDING AG	-9.90%	193B
PFIZER, INC.	-12.26%	143B
AMGEN INC.	-6.47%	144B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-04-25 pm EDT			Pre-market 07:54:23 am
44.7 ^USD	-8.51%		44.72	+0.06%

01:54pm	Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating	MT
01:24pm	BMO Capital Adjusts Price Target on Bristol-Myers Squibb Company to $48 From $55	MT

Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating	07:54am	MT
BMO Capital Adjusts Price Target on Bristol-Myers Squibb Company to $48 From $55	07:24am	MT
Health Care Drops Amid Mixed Earnings -- Health Care Roundup	Apr. 25	DJ
Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 25	MT
Sector Update: Health Care Stocks Drop in Afternoon Trading	Apr. 25	MT
Sector Update: Health Care	Apr. 25	MT
Jefferies Adjusts Bristol-Myers Squibb Price Target to $54 From $56, Keeps Hold Rating	Apr. 25	MT
Bristol-Myers Squibb Swings to Q1 Non-GAAP Loss, Revenue Rises; Provides 2024 Guidance -- Shares Fall	Apr. 25	MT
Cantor Fitzgerald Adjusts Price Target on Bristol-Myers Squibb to $45 From $52, Maintains Neutral Rating	Apr. 25	MT
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco...	Apr. 25
Stocks in motion: Large caps struggle	Apr. 25
Trending : Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts	Apr. 25	DJ
The specter of stagflation rears its ugly head again	Apr. 25
Bristol Myers Shedding 2,200 Jobs in Cost Savings Push	Apr. 25	DJ
Bristol-Myers Squibb Swings to Q1 Non-GAAP Loss, Revenue Rises; Provides 2024 Guidance	Apr. 25	MT
Bristol Myers: heavy quarterly loss on charges	Apr. 25	CF
Transcript : Bristol-Myers Squibb Company, Q1 2024 Earnings Call, Apr 25, 2024	Apr. 25
Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss	Apr. 25	DJ
(BMY) BRISTOL MYERS SQUIBB Sees Fiscal Year 2024 EPS Range $0.40 - $0.70	Apr. 25	MT
Earnings Flash (BMY) BRISTOL MYERS SQUIBB Posts Q1 Revenue $11.87B, vs. Street Est of $11.45B	Apr. 25	MT
Futures Decline Pre-Bell Ahead of Earnings, Economic Reports; Asia Churns, Europe Down	Apr. 25	MT
Bristol-Myers Squibb Company Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Bristol Myers posts quarterly loss, revenue rises 5%	Apr. 25	RE
Futures falter as Meta Platforms weighs on megacaps	Apr. 25	RE
Germany's Evotec appoints Christian Wojczewski as CEO	Apr. 23	RE